Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach - Takeaways - MDSpire

Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach

  • By

  • Masumi Ueda Oshima

  • Brenda M. Sandmaier

  • Effie Petersdorf

  • Mary E. Flowers

  • Geoffrey R. Hill

  • Stephanie J. Lee

  • Frederick R. Appelbaum

  • Paul A. Carpenter

  • K. Scott Baker

  • Laura Connelly-Smith

  • Andrea McCool

  • Suni Elgar

  • Steven A. Pergam

  • Catherine Liu

  • F. Marc Stewart

  • Marco Mielcarek

  • September 26, 2020

  • 0 min

Share

  • 1

    The Seattle BMT Program adapted rapidly to COVID-19 by implementing extensive infection prevention measures and deferring nonurgent procedures.

  • 2

    By July 2020, King County had a significant proportion of Washington's COVID-19 cases, prompting urgent changes in patient care protocols.

  • 3

    Telehealth visits were introduced to maintain communication with patients while minimizing COVID-19 exposure during the pandemic.

  • 4

    A biweekly BMT COVID-19 committee was established to discuss practice changes and ensure operational continuity amid the evolving situation.

  • 5

    The BMT unit enhanced its infrastructure by creating additional negative pressure rooms to care for transplant patients infected with COVID-19.

Original Source(s)

Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach

  • by Masumi Ueda Oshima, Brenda M. Sandmaier, Effie Petersdorf, Mary E. Flowers, Geoffrey R. Hill, Stephanie J. Lee, Frederick R. Appelbaum, Paul A. Carpenter, K. Scott Baker, Laura Connelly-Smith, Andrea McCool, Suni Elgar, Steven A. Pergam, Catherine Liu, F. Marc Stewart, Marco Mielcarek

  • September 26, 2020

Related Content

Mendelian Randomization and Infection: Pitfalls and Promises

Journal of the Pediatric Infectious Diseases Society and the Journal of Infectious Diseases Collaboration: The First Fruits From a New Tree

Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study